These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 36282673)

  • 41. [Successful detection of MYD88 L265P mutation in Waldenström's macroglobulinemia complicated with myelofibrosis using highly sensitive digital PCR].
    Nawata R; Sugiyama A; Harada K; Shinohara K; Yujiri T
    Rinsho Ketsueki; 2019; 60(8):903-909. PubMed ID: 31484887
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naïve patients with Waldenstrom macroglobulinemia.
    Paludo J; Abeykoon JP; Kumar S; Shreders A; Ailawadhi S; Gertz MA; Kourelis T; King RL; Reeder CB; Leung N; Kyle RA; Buadi FK; Habermann TM; Dingli D; Witzig TE; Dispenzieri A; Lacy MQ; Go RS; Lin Y; Gonsalves WI; Warsame R; Lust JA; Rajkumar SV; Ansell SM; Kapoor P
    Br J Haematol; 2017 Oct; 179(1):98-105. PubMed ID: 28786474
    [TBL] [Abstract][Full Text] [Related]  

  • 43. How Recent Advances in Biology of Waldenström's Macroglobulinemia May Affect Therapy Strategy.
    Baron M; Simon L; Poulain S; Leblond V
    Curr Oncol Rep; 2019 Feb; 21(3):27. PubMed ID: 30806816
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Novel approaches to targeting MYD88 in Waldenström macroglobulinemia.
    Castillo JJ; Hunter ZR; Yang G; Treon SP
    Expert Rev Hematol; 2017 Aug; 10(8):739-744. PubMed ID: 28617062
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Monoclonal gammopathy of undetermined significance and Waldenström's macroglobulinemia.
    Mailankody S; Landgren O
    Best Pract Res Clin Haematol; 2016 Jun; 29(2):187-193. PubMed ID: 27825465
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Waldenström macroglobulinemia: 2023 update on diagnosis, risk stratification, and management.
    Gertz MA
    Am J Hematol; 2023 Feb; 98(2):348-358. PubMed ID: 36588395
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Zanubrutinib for the treatment of Waldenström Macroglobulinemia.
    Lim KJC; Tam CS
    Expert Rev Hematol; 2020 Dec; 13(12):1303-1310. PubMed ID: 33297772
    [No Abstract]   [Full Text] [Related]  

  • 48. What is new in the treatment of Waldenstrom macroglobulinemia?
    Castillo JJ; Treon SP
    Leukemia; 2019 Nov; 33(11):2555-2562. PubMed ID: 31591468
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Treatment recommendations in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
    Gertz MA; Anagnostopoulos A; Anderson K; Branagan AR; Coleman M; Frankel SR; Giralt S; Levine T; Munshi N; Pestronk A; Rajkumar V; Treon SP
    Semin Oncol; 2003 Apr; 30(2):121-6. PubMed ID: 12720120
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Bortezomib in relapsed or refractory Waldenström's macroglobulinemia.
    Chen C; Kouroukis CT; White D; Voralia M; Stadtmauer E; Stewart AK; Wright JJ; Powers J; Walsh W; Eisenhauer E
    Clin Lymphoma Myeloma; 2009 Mar; 9(1):74-6. PubMed ID: 19362979
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evaluating ibrutinib in the treatment of symptomatic Waldenstrom's macroglobulinemia.
    Papanota AM; Ntanasis-Stathopoulos I; Kastritis E; Dimopoulos MA; Gavriatopoulou M
    J Blood Med; 2019; 10():291-300. PubMed ID: 31695539
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Detection of the MYD88
    Wu YY; Jia MN; Cai H; Qiu Y; Zhou DB; Li J; Cao XX
    Ann Hematol; 2020 Aug; 99(8):1763-1769. PubMed ID: 32577844
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia.
    Treon SP; Cao Y; Xu L; Yang G; Liu X; Hunter ZR
    Blood; 2014 May; 123(18):2791-6. PubMed ID: 24553177
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Detection of MYD88 and CXCR4 mutations in cell-free DNA of patients with IgM monoclonal gammopathies.
    Bagratuni T; Ntanasis-Stathopoulos I; Gavriatopoulou M; Mavrianou-Koutsoukou N; Liacos C; Patseas D; Kanellias N; Migkou M; Ziogas DC; Eleutherakis-Papaiakovou E; Roussou M; Fotiou D; Terpos E; Kastritis E; Dimopoulos MA
    Leukemia; 2018 Dec; 32(12):2617-2625. PubMed ID: 30026568
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Successful treatment of refractory cold hemagglutinemia in MYD88 L265P mutation-negative Waldenström's macroglobulinemia with bortezomib.
    Izumi M; Tsunemine H; Suzuki Y; Tomita A; Kusumoto T; Kodaka T; Itoh K; Takahashi T
    Int J Hematol; 2015 Aug; 102(2):238-43. PubMed ID: 25794560
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Future therapeutic options for patients with Waldenström macroglobulinemia.
    Castillo JJ; Hunter ZR; Yang G; Argyropoulos K; Palomba ML; Treon SP
    Best Pract Res Clin Haematol; 2016 Jun; 29(2):206-215. PubMed ID: 27825467
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical and molecular characteristics of lymphoplasmacytic lymphoma not associated with an IgM monoclonal protein: A multicentric study of the Rete Ematologica Lombarda (REL) network.
    Varettoni M; Boveri E; Zibellini S; Tedeschi A; Candido C; Ferretti VV; Rizzo E; Doni E; Merli M; Farina L; Goldaniga M; Gallì A; Rattotti S; Frustaci AM; Deodato M; Bandiera L; Isimbaldi G; Uccella S; Cabras AD; Gianelli U; Baldini L; Paulli M; Arcaini L
    Am J Hematol; 2019 Nov; 94(11):1193-1199. PubMed ID: 31378966
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Characteristics of Waldenström Macroglobulinemia in Korean Patients According to Mutational Status of MYD88 and CXCR4: Analysis Using Ultra-Deep Sequencing.
    Shin DW; Kim SM; Kim JA; Park HS; Hwang SM; Im K; Kim S; Kim J; Kwon S; Yoon SS; Lee DS
    Clin Lymphoma Myeloma Leuk; 2019 Aug; 19(8):e496-e505. PubMed ID: 31221512
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Management of Waldenström macroglobulinemia in 2020.
    Castillo JJ; Treon SP
    Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):372-379. PubMed ID: 33275726
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Case report: A rare case of coexisting Waldenstrom Macroglobulinemia and B-cell acute lymphoblastic leukemia with KMT2D and MECOM mutations.
    Wang L; Tang J; Feng J; Huang Y; Cheng Y; Xu H; Miao Y
    Front Immunol; 2022; 13():1001482. PubMed ID: 36325357
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.